<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520011</url>
  </required_header>
  <id_info>
    <org_study_id>TPI-ALV-201</org_study_id>
    <nct_id>NCT02520011</nct_id>
  </id_info>
  <brief_title>Alvocidib Biomarker-driven Phase 2 AML Study</brief_title>
  <official_title>A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tolero Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tolero Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete
      Remission) to FLAM compared to AM treatment in refractory or relapsed AML patients with
      demonstrated NOXA BH3 priming of ≥ 40% by mitochondrial profiling in bone marrow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Stage 1 of the study, all eligible AML patients with demonstrated NOXA BH3 priming of ≥
      40% by mitochondrial profiling in bone marrow will receive treatment with alvocidib,
      cytarabine and mitoxantrone [ACM ('FLAM') regimen].

      In Stage 2, all eligible AML patients with demonstrated NOXA BH3 priming of ≥ 40% by
      mitochondrial profiling in bone marrow will be randomized 1:1 to receive either treatment
      with ACM or CM (cytarabine and mitoxantrone).

      In the NDHR exploratory arm, all eligible patients with newly diagnosed high-risk (NDHR) AML
      with NOXA BH3 priming ≥40% by mitochondrial profiling in bone marrow will receive treatment
      with ACM.

      In the NOXA exploratory arm, all eligible AML patients with demonstrated NOXA BH3 priming of
      ≥ 30 - 39% by mitochondrial profiling in bone marrow will receive treatment with ACM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission (CR) rate = Percentage of patients achieving CR</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Day 1 until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined CR Rate = Percentage of patients achieving CR, CRi, CRp</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Response Rate = Percentage of patients achieving CR, CRi, CRp, PR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stem Cell Transplantation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>30 and 60 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ACM (Stage 1 / Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM (Stage 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Arm - NDHR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory Arm - NOXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvocidib</intervention_name>
    <arm_group_label>ACM (Stage 1 / Stage 2)</arm_group_label>
    <arm_group_label>Exploratory Arm - NDHR</arm_group_label>
    <arm_group_label>Exploratory Arm - NOXA</arm_group_label>
    <other_name>flavopiridol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>ACM (Stage 1 / Stage 2)</arm_group_label>
    <arm_group_label>CM (Stage 2)</arm_group_label>
    <arm_group_label>Exploratory Arm - NDHR</arm_group_label>
    <arm_group_label>Exploratory Arm - NOXA</arm_group_label>
    <other_name>ara-c</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>ACM (Stage 1 / Stage 2)</arm_group_label>
    <arm_group_label>CM (Stage 2)</arm_group_label>
    <arm_group_label>Exploratory Arm - NDHR</arm_group_label>
    <arm_group_label>Exploratory Arm - NOXA</arm_group_label>
    <other_name>mitoxantrone hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be between the ages of ≥18 and ≤65 years

          2. Have an established, pathologically confirmed diagnoses of AML by World Health
             Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a
             bone marrow of &gt;5% blasts based on histology or flow cytometry

          3. Be in first relapse (within 24 months of CR) or have primary refractory AML
             (refractory to initial induction therapy using 1 or 2 cycles of intensive
             anthracycline/cytarabine ± etoposide or cladribine induction) or have newly diagnosed
             high-risk AML as defined in this protocol.

          4. Demonstrate NOXA BH3 priming of ≥40% by mitochondrial profiling in bone marrow or 30 -
             39% for NOXA Exploratory Arm.

          5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2

          6. Have a serum creatinine level ≤1.8 mg/dL

          7. Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times
             upper limit of normal (ULN)

          8. Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome,
             hemolysis, or leukemia)

          9. Have a left ventricular ejection fraction (LVEF) &gt;45% by echocardiogram (ECHO) or
             multigated acquisition (MUGA) scan

         10. Be nonfertile or agree to use an adequate method of contraception. Sexually active
             patients and their partners must use an effective method of contraception associated
             with a low failure rate during and for 6 months after completion of study therapy.

         11. Be able to comply with the requirements of the entire study.

         12. Provide written informed consent prior to any study related procedure.

        Exclusion Criteria:

          1. Received more than 2 cycles of induction therapy for AML. Investigational agents as
             part of front-line therapy for AML may by acceptable following discussion with the
             Medical Monitor. Hydroxyurea is permitted (see #5 below).

          2. Received any previous treatment with alvocidib or any other CDK inhibitor

          3. Received a hematopoietic stem cell transplant within the previous 2 months

          4. Have clinically significant graft versus host disease (GVHD), or GVHD requiring
             initiation or escalation of treatment within the last 21 days

          5. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is
             allowed up to the evening before starting (but not within 12 hours) of starting
             treatment on either arm.

          6. Received &gt;360 mg/m2 equivalents of daunorubicin

          7. Have a peripheral blast count of &gt;30,000/mm3 (may use hydroxyurea as in #5 above)

          8. Received antileukemic therapy within the last 3 weeks (with the exception of
             hydroxyurea or if the patient has definite refractory disease). Refractory patients
             who received therapy within the last 3 weeks may be eligible with prior approval of
             the Medical Monitor.

          9. Diagnosed with acute promyelocytic leukemia (APL, M3)

         10. Have active central nervous system (CNS) leukemia

         11. Have evidence of uncontrolled disseminated intravascular coagulation

         12. Have an active, uncontrolled infection

         13. Have other life-threatening illness

         14. Have other active malignancies or diagnosed with other malignancies within the last 6
             months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia

         15. Have mental deficits and/or psychiatric history that may compromise the ability to
             give written informed consent or to comply with the study protocol.

         16. Are pregnant and/or nursing

         17. Have received any live vaccine within 14 days prior to first study drug
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Anthony, DO</last_name>
    <role>Study Director</role>
    <affiliation>Tolero Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Costas, BSN</last_name>
    <phone>3616499176</phone>
    <email>jcostas@toleropharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Shegda</last_name>
      <phone>404-845-5929</phone>
      <email>nancy.mccarthy@Northside.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Parrott, RN, BSN</last_name>
      <phone>319-353-6347</phone>
      <email>karen-parrott@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Vigil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tara Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery</last_name>
      <phone>504-842-0275</phone>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Dalovisio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seanna Coffin</last_name>
      <phone>410-614-2023</phone>
      <email>scoffin1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>B. Douglas Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Cancer Center</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyaw Htun</last_name>
      <phone>914-493-8375</phone>
      <email>khtun@nymc.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Seiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Leach</last_name>
      <phone>212-304-5585</phone>
      <email>sl3971@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Frattini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Zhang</last_name>
      <email>jack_zhang@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Zeidner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Rizzieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Brigham</last_name>
      <phone>252-744-4924</phone>
      <email>brighamd16@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Darla Liles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Solis</last_name>
      <phone>214-820-8685</phone>
      <email>amy.solis@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Moshe Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Bivins</last_name>
      <phone>713-794-4460</phone>
      <email>cbibins@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jorge Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayden Krause</last_name>
      <phone>414-805-0596</phone>
      <email>hkrause@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ehab Atallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Sanfelice, RN</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2867</phone_ext>
      <email>karen.yee@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Karen Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory AML</keyword>
  <keyword>Relapsed AML</keyword>
  <keyword>AML</keyword>
  <keyword>Newly diagnosed high-risk AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

